Inhibition or suppression of BCMA expression may be an essential mechanism for disease progression that requires further investigation.97,98 Different approaches to BCMA in cell therapy, engineering cells for MM, are also being studied.94 Another target is CD138 (Syndecan 1), which is highly expressed in MM cells and is associated with disease pathogenesis. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.